Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Clinical Relevance of Domain-Specific Phospholipase A 2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy.

BACKGROUND: Antibodies against phospholipase A2 receptor 1 (PLA2 R1) are found in 80% of patients with membranous nephropathy, and previous studies described three autoantibody-targeted PLA2 R1 epitope regions. Although anti-PLA2 R1 antibody levels are closely associated with treatment response and disease prognosis, the clinical role of epitope regions targeted by autoantibodies is unclear.

METHODS: In a prospective cohort of 150 patients with newly diagnosed PLA2 R1-associated membranous nephropathy, we investigated the clinical role of epitope-recognition patterns and domain-specific PLA2 R1 antibody levels by western blot and ELISA.

RESULTS: We identified a fourth epitope region in the CTLD8 domain of PLA2 R1, which was recognized by anti-PLA2 R1 antibodies in 24 (16.0%) patients. In all study patients, anti-PLA2 R1 antibodies bound both the N-terminal (CysR-FnII-CTLD1) region and the C-terminal (CTLD7-CTLD8) region of PLA2 R1 at study enrollment. The total anti-PLA2 R1 antibody levels of patients determined detection of domain-specific PLA2 R1 antibodies, and thereby epitope-recognition patterns. A remission of proteinuria occurred in 133 (89%) patients and was not dependent on the domain-recognition profiles. A newly developed ELISA showed that domain-specific PLA2 R1 antibody levels targeting CysR, CTLD1, and CTLD7 strongly correlate with the total anti-PLA2 R1 antibody level (Spearman's rho, 0.95, 0.64, and 0.40; P <0.001, P <0.001, and P =0.002, respectively) but do not predict disease outcome independently of total anti-PLA2 R1 antibody levels.

CONCLUSIONS: All patients with PLA2 R1-associated membranous nephropathy recognize at least two epitope regions in the N- and C-terminals of PLA2 R1 at diagnosis, contradicting the hypothesis that PLA2 R1 "epitope spreading" determines the prognosis of membranous nephropathy. Total anti-PLA2 R1 antibody levels, but not the epitope-recognition profiles at the time of diagnosis, are relevant for the clinical outcome of patients with this disease.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app